Press Room


    Press Release - December 16, 2010

    Prominent Transplant Surgeon, Dr. Steven Paraskevas, Joins Sernova Scientific Advisory Board

    Source: Sernova Corp


    December 16, 2010, 6:00 a.m. EDT

    LONDON, ONTARIO--(Marketwire -- December 16, 2010) - Sernova Corp. (TSX-V: SVA), is pleased to announce the appointment of Dr. Steven Paraskevas, MD, Ph.D., to the Corporation's Scientific Advisory Board. Dr. Paraskevas is transplant surgeon at McGill University Health Centre and Director of the Pancreas and Islet Transplant Program and of the Human Islet Isolation Laboratory at McGill.

    "Dr. Paraskevas is highly respected in the islet transplant field and will be an excellent addition to Sernova's clinical development team working on the Cell Pouch(TM)," said Dr. James Shapiro, MD, Ph.D. FRCS (Eng.) FRCSC, Director of the Clinical Islet Transplantation Program at the University of Alberta and member of Sernova's scientific advisory board.

    "The new islet transplantation program at McGill University headed by Dr. Paraskevas is the third such centre in Canada and provides the potential to significantly increase the number of diabetic patients that can be treated with donor islets. This advancement will not only benefit diabetic patients but will be advantageous to Sernova as it prepares for clinical development of the Cell Pouch(TM)," noted Dr. Philip Toleikis, President & CEO of Sernova Corp.

    Dr Paraskevas earned a BA in Biology at Harvard University in 1988, and obtained his MD and completed General Surgery residency at McGill. During that time, he also studied mechanisms of cell death in transplanted human islets, completing a PhD in Experimental Surgery at McGill in 2003. Based on this work, he earned the Scientific Trainee Award of the Canadian Diabetes Association in 1997. After residency, he completed a two- year fellowship in abdominal solid-organ transplantation at the University of Minnesota, where he was also involved in the clinical islet transplant program under Dr Bernhard Hering. He returned to McGill in 2002 and is currently Associate Professor in Surgery and member of the multi- organ transplant program.

    His current research focuses on methods to improve islet survival of human islets, paralleling the focus of Sernova's proprietary technologies. He is a Councillor-at- large of the Canadian Society of Transplantation and Chair of the Cell Transplant Committee of the American Society of Transplant Surgeons.

    "Sernova is developing an eminent team of clinicians to lead the clinical evaluation of the Cell Pouch(TM) and we are thrilled to have Dr. Paraskevas as a member of that team, added Dr. David White, Chairman of Sernova's Scientific Advisory Board.

    Sernova's Cell Pouch System(tm) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas when infused with islets. The natural environment established by the Cell Pouch System(tm) is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

    For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News